Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: A systematic review and meta-analysis

Thrombosis Research

Volumn 135, Issue 4, 2015, Pages 739-747

  Sun, Yifan ^a   Wu, Zhitong ^b   Li, Shan ^c   Qin, Xue ^c   Li, Taijie ^c   Xie, Li ^c   Deng, Yan ^c   Chen, Junqing ^c  

^a The Third Clinical Faculty of Guangxi University of Chinese Medicine   (China)

^b Guigang People's Hospital   (China)

^c GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Gamma glutamyl carboxylase; Meta analysis; Polymorphism; Warfarin

Indexed keywords

CARBOXYLASE; GAMMA GLUTAMYL CARBOXYLASE; UNCLASSIFIED DRUG; WARFARIN; ANTICOAGULANT AGENT; GLUTAMYL CARBOXYLASE; LIGASE;

ALLELE; ARTICLE; BRAIN ISCHEMIA; DEEP VEIN THROMBOSIS; ETHNICITY; GENE EXPRESSION; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEART ATRIUM FIBRILLATION; HEART VALVE REPLACEMENT; HUMAN; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; GENETIC POLYMORPHISM; GENETICS;

ANTICOAGULANTS; CARBON-CARBON LIGASES; HUMANS; POLYMORPHISM, GENETIC; WARFARIN;

EID: 84924963124     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2015.01.029     Document Type: Article

References (45)

1. D.K. Wysowski, P. Nourjah, and L. Swartz Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action Arch Intern Med 167 13 2007 1414 1419
2. L. Miao, J. Yang, C. Huang, and Z. Shen Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients Eur J Clin Pharmacol 63 12 2007 1135 1141
3. K.M. Momary, N.L. Shapiro, M.A. Viana, E.A. Nutescu, C.M. Helgason, and L.H. Cavallari Factors influencing warfarin dose requirements in African-Americans Pharmacogenomics 8 11 2007 1535 1544
4. D.S. Budnitz, N. Shehab, S.R. Kegler, and C.L. Richards Medication use leading to emergency department visits for adverse drug events in older adults Ann Intern Med 147 11 2007 755 765
5. H. Takahashi, G.R. Wilkinson, E.A. Nutescu, T. Morita, M.D. Ritchie, and M.G. Scordo Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans Pharmacogenet Genomics 16 2 2006 101 110
6. G. D'Andrea, R.L. D'Ambrosio, P. Di Perna, M. Chetta, R. Santacroce, and V. Brancaccio A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin Blood 105 2 2005 645 649
7. M.D. Caldwell, T. Awad, J.A. Johnson, B.F. Gage, M. Falkowski, and P. Gardina CYP4F2 genetic variant alters required warfarin dose Blood 111 8 2008 4106 4112
8. D. Herman, P. Peternel, M. Stegnar, K. Breskvar, and V. Dolzan The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement Thromb Haemost 95 5 2006 782 787
9. M. Wadelius, L.Y. Chen, K. Downes, J. Ghori, S. Hunt, and N. Eriksson Common VKORC1 and GGCX polymorphisms associated with warfarin dose Pharmacogenomics J 5 4 2005 262 270
10. D.J. Harrington, S. Underwood, C. Morse, M.J. Shearer, E.G. Tuddenham, and A.D. Mumford Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1 Thromb Haemost 93 1 2005 23 26
11. R. Loebstein, M. Vecsler, D. Kurnik, N. Austerweil, E. Gak, and H. Halkin Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P450 2C9 Clin Pharmacol Ther 77 5 2005 365 372
12. R. Kimura, K. Miyashita, Y. Kokubo, Y. Akaiwa, R. Otsubo, and K. Nagatsuka Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients Thromb Res 120 2 2007 181 186
13. M. Ohno, A. Yamamoto, A. Ono, G. Miura, M. Funamoto, and Y. Takemoto Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients Eur J Clin Pharmacol 65 11 2009 1097 1103
14. Y.Z.S.L. Liu, M. Yang, H.H. Tang, and H.W. Fei Impact of gamma-glutamyl carboxylase gene genovariation in Chinese Han population on the response of warfarin initial anticoagulant therapy. South China J Cardiol 12 4 2010 203 209
15. J.R. Choi, J.O. Kim, D.R. Kang, S.A. Yoon, J.Y. Shin, and X. Zhang Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients J Hum Genet 56 4 2011 290 295
16. S.L. Zhong, X.Y. Yu, Y. Liu, D. Xu, L.P. Mai, and H.H. Tan Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients Pharmacogenet Genomics 22 3 2012 176 182
17. S.W. Huang, D.K. Xiang, H.L. Wu, B.L. Chen, B.Q. An, and G.F. Li Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28 6 2011 661 665
18. C.R. King, E. Deych, P. Milligan, C. Eby, P. Lenzini, and G. Grice Gamma-glutamyl carboxylase and its influence on warfarin dose Thromb Haemost 104 4 2010 750 754
19. S. Rost, A. Fregin, D. Koch, M. Compes, C.R. Muller, and J. Oldenburg Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors Br J Haematol 126 4 2004 546 549
20. A. Zhu, H. Sun, R.M. Raymond Jr., B.C. Furie, B. Furie, and M. Bronstein Fatal hemorrhage in mice lacking gamma-glutamyl carboxylase Blood 109 12 2007 5270 5275
21. M.D. Crosier, I. Peter, S.L. Booth, G. Bennett, B. Dawson-Hughes, and J.M. Ordovas Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status J Nutr Sci Vitaminol 55 2 2009 112 119
22. Y. Liang, Z. Chen, G. Guo, X. Dong, C. Wu, and H. Li Association of genetic polymorphisms with warfarin dose requirements in Chinese patients Genet Test Mol Biomarkers 17 12 2013 932 936
23. H. Schelleman, C.M. Brensinger, J. Chen, B.S. Finkelman, M.J. Rieder, and S.E. Kimmel New genetic variant that might improve warfarin dose prediction in African Americans Br J Clin Pharmacol 70 3 2010 393 399
24. M. Vecsler, R. Loebstein, S. Almog, D. Kurnik, B. Goldman, and H. Halkin Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin Thromb Haemost 95 2 2006 205 211
25. Y. Lou The Study of Warfarin Maintenance Dose Algorithm in Chinese Han Population [PHD] 2012 Peking Union Medical College
26. D. Krishna Kumar, D.G. Shewade, M.A. Loriot, P. Beaune, J. Balachander, and B.V. Sai Chandran Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population Eur J Clin Pharmacol 70 1 2014 47 56
27. S.S. Rathore, S.K. Agarwal, S. Pande, S.K. Singh, T. Mittal, and B. Mittal CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant Indian J Med Res 139 4 2014 572 578
28. E. Wypasek, A. Branicka, M. Awsiuk, J. Sadowski, and A. Undas Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: A potential role of CYP4F2 and GGCX polymorphisms Thromb Res 134 3 2014 604 609
29. G. Lippi, G. Targher, M. Montagnana, G.L. Salvagno, G. Zoppini, and G.C. Guidi Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients Arch Pathol Lab Med 133 4 2009 628 632
30. Y. Koma, A. Onishi, H. Matsuoka, N. Oda, N. Yokota, and Y. Matsumoto Increased red blood cell distribution width associates with cancer stage and prognosis in patients with lung cancer PLoS One 8 11 2013 e80240
31. L. Yang, W. Ge, F. Yu, and H. Zhu Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-A systematic review and meta analysis Thromb Res 125 4 2010 e159 e166
32. P.C. Cha, T. Mushiroda, A. Takahashi, S. Saito, H. Shimomura, and T. Suzuki High-resolution SNP and haplotype maps of the human gamma-glutamyl carboxylase gene (GGCX) and association study between polymorphisms in GGCX and the warfarin maintenance dose requirement of the Japanese population J Hum Genet 52 10 2007 856 864
33. O.A. Dada, E. Uche, A. Akinbami, M. Odesanya, S. John-Olabode, and A. Adediran The relationship between red blood cell distribution width and blood pressure in patients with type 2 diabetes mellitus in Lagos, Nigeria J Blood Med 5 2014 185 189
34. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Ann Intern Med 151 4 2009 264 269
35. J. Little, L. Bradley, M.S. Bray, M. Clyne, J. Dorman, and D.L. Ellsworth Reporting, appraising, and integrating data on genotype prevalence and gene-disease associations Am J Epidemiol 156 4 2002 300 310
36. J.D. Lindh, L. Holm, M.L. Andersson, and A. Rane Influence of CYP2C9 genotype on warfarin dose requirements-A systematic review and meta-analysis Eur J Clin Pharmacol 65 4 2009 365 375
37. J. Higgins, and S.G. Thompson Quantifying heterogeneity in a metaaanalysis Stat Med 21 11 2002 1539 1558
38. J.P. Higgins, S.G. Thompson, J.J. Deeks, and D.G. Altman Measuring inconsistency in meta-analyses Br Med J 327 7414 2003 557
39. J.F. Carlquist, B.D. Horne, J.B. Muhlestein, D.L. Lappe, B.M. Whiting, and M.J. Kolek Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study J Thromb Thrombolysis 22 3 2006 191 197
40. C. Geisen, M. Watzka, K. Sittinger, M. Steffens, L. Daugela, and E. Seifried VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation Thromb Haemost 94 4 2005 773 779
41. S. Albayrak, K. Zengin, S. Tanik, H. Bakirtas, A. Imamoglu, and M. Gurdal Red cell distribution width as a predictor of prostate cancer progression Asian Pac J Cancer Prev 15 18 2014 7781 7784
42. A. Blann, J. Hewitt, F. Siddiqui, and D. Bareford Racial background is a determinant of average warfarin dose required to maintain the INR between 2.0 and 3.0 Br J Haematol 107 1 1999 207 209
43. M.T. Dang, J. Hambleton, and S.R. Kayser The influence of ethnicity on warfarin dosage requirement Ann Pharmacother 39 6 2005 1008 1012
44. The Japanese Circulation Society Guidelines for pharmacotherapy of Atrial Fibrillation (JCS 2008) Circ J 72 2008 1581 1638
45. W.L. Baker, and K.W. Chamberlin New oral anticoagulants vs. warfarin treatment: no need for pharmacogenomics? Clin Pharmacol Ther 96 1 2014 17 19